


 Cite this: *RSC Adv.*, 2020, **10**, 7912

# Electrochemical immunosensor based on AuBP@Pt nanostructure and AuPd-PDA nanozyme for ultrasensitive detection of APOE4†

Yibiao Liu, \* Guangli He, Huili Liu, Hang Yin, Fengli Gao, Jian Chen, \* Shouren Zhang and Baocheng Yang

An ultrasensitive sandwich-type electrochemical immunosensor based on AuBP@Pt nanostructures and AuPd-PDA nanozyme was developed for the detection of apolipoprotein E4 (APOE4) which was an important risk factor for Alzheimer's disease (AD). In this work, gold nanobipyramid coated Pt (AuBP@Pt) nanostructures were prepared and applied to electrochemical immunosensors as a substrate material. AuBP@Pt nanostructures have advantages of electrical conductivity and large electroactive area, which could greatly increase electron transfer rate. In previous work, we designed AuPd alloy modified polydopamine (AuPd-PDA) nanozyme which catalyzed the decomposition of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). AuPd-PDA nanozyme was used to label detection antibody due to excellent catalytic capability and stability in this new paper. And the concentration of APOE4 could be detected quantitatively by variation for transient current. As a result, the electrochemical immunosensor based on AuBP@Pt and AuPd-PDA exhibited a wide linear range from 0.05 to 2000 ng mL<sup>-1</sup> and low detection limit of 15.4 pg mL<sup>-1</sup> (S/N = 3). Furthermore, the designed biosensor displayed good selectivity in phosphate buffer saline (PBS) buffer solution or commercial goat serum, which provided a promising tool for early diagnosis of AD.

 Received 11th January 2020  
 Accepted 16th February 2020

DOI: 10.1039/d0ra00298d

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

Human apolipoprotein E4 (APOE4), a 34-kDa protein containing 299 amino acids, exacerbates Alzheimer's disease (AD) through promoting the formation of cerebral extracellular amyloid plaques and inhibiting the clearance of Aβ aggregates. Furthermore, APOE4 increased permeability of blood–brain barrier (BBB) and finally led to BBB breakdown.<sup>1–3</sup> Lots of evidence including biochemical, cellular and clinical studies have demonstrated that APOE4 is closely related to AD pathogenesis.<sup>4,5</sup> Based on the key role in AD pathogenesis, APOE4 has been widely recognized as a potential biomarker for AD diagnosis. Therefore, timely and accurate detection of APOE4 is significant for prevention and early diagnosis of AD and it is very necessary to develop ultrasensitive, high selectivity and easy detection methods.

In the past few years, some traditional techniques such as mass spectrometry (MS),<sup>6,7</sup> enzyme-linked immunosorbent assays (ELISA) and western-blot analysis<sup>8,9</sup> were used to detect

APOE. However, these methods are flawed due to being low sensitivity, time-consuming, with high cost and requirement of specific equipment. In recent years, some new technologies including microarray technology,<sup>10</sup> surface plasmon resonance (SPR),<sup>11</sup> and electrochemistry immunosensors<sup>12</sup> were applied to detect human APOE. Among these methods, electrochemical immunosensors have caused widespread attention due to many superiorities including rapid detection, high sensitivity and low cost.<sup>13,14</sup> With the rapid development of nanotechnology, nanomaterials have been widely applied to electrochemical biosensing by reason of their large electroactive area, excellent biocompatibility and unique physical/chemical properties, which makes ultrasensitive detection possible. So far, a lot of studies proved that many nanomaterials with interesting morphologies, such as 3D metal–organic frameworks,<sup>15</sup> nanoparticles,<sup>16</sup> nanowires,<sup>17</sup> quantum dots,<sup>18</sup> fractal structures<sup>12</sup> and large amounts of nanocomposites,<sup>19–21</sup> significantly enhanced the sensitivity of the electrochemical biosensor and decreased the detection limit.

Recently, bimetallic nanostructures have caught more attention due to their integration of physicochemical properties including plasmonic functionality, optical property, magnetism, catalytic performance and electrical conductivity.<sup>22,23</sup> For instance, Au–Pd alloy could catalyze organic reactions.<sup>24</sup> Yan Liu *et al.* designed a sandwich-like electrochemical immunosensor for the detection of carbohydrate antigen based on hierarchical AuPd nanochain networks.<sup>25</sup> Recently, our group reported

Department of Henan Key Laboratory of Nanocomposites and Applications, Institute of Nanostructured Functional Materials, Huanghe Science and Technology College, Zhengzhou 450006, China. E-mail: liuyibiao12345@126.com; jianchen@infm.hhstu.edu.cn

† Electronic supplementary information (ESI) available: The Reproducibility, selectivity, stability of the electrodes and some additional supporting information. See DOI: 10.1039/d0ra00298d



a  $\text{H}_2\text{O}_2$  electrochemical sensor based on AuPd alloy-modified polydopamine nanotubes (AuPd-PDA).<sup>26</sup> AuPd-PDA nano-enzyme showed excellent catalytic activities and good stability, which could be applied to biosensor in replace of HRP in some ways. Not only that, PDA nanotubes also had many advantages including good biocompatibility, large specific surface area and unique optoelectronic properties,<sup>27,28</sup> which could be applied for signal acquisition and signal amplification as a carrier and thus improved the sensitivity of electrochemical immunosensors.

In this work, another bimetallic nanostructure, gold nanopipyramid coated Pt (AuBP@Pt) was prepared. AuBP@Pt nanostructures have good conductivity and could increase the electroactive area due to porous surface though its catalytic activity was bad (Fig. 3a and S1†). Therefore, AuBP@Pt was used to modify the electrode as a substrate material, which could greatly increase the sensitivity of sensor. Furthermore, detection antibody labelled AuPd-PDA ( $\text{Ab}_2$  label) was used to amplify signal again as a whole because of the excellent catalytic capabilities for  $\text{H}_2\text{O}_2$  (ref. 26) and large surface areas. The fabrication procedure for  $\text{Ab}_2$  label was shown in Fig. 1a. In the sensing system, AuPd-PDA replaced the traditional bio-enzyme which had drawback of easier deactivation. According to previous report,<sup>29</sup> the combination of AuPd-PDA and  $\text{Ab}_2$  was characterized by FTIR as seen in Fig. S2.† The detailed description was shown in ESI.†

Based on AuBP@Pt nanomaterials and AuPd-PDA nano-enzyme, we constructed an APOE4 electrochemical immunosensor, which exhibited high sensitivity and low detection limit in phosphate buffered saline (PBS) or commercial goat serum. The schematic illustration of the fabricated APOE4 electrochemical immunosensor was shown in Fig. 1b. The electrochemical immunosensor included working electrode and electrochemical detection system. Firstly, Au nanoparticles that had advantages of good biocompatible and excellent

conductivity were electrodeposited on the surface of GCE, which increased the binding site of primary antibody ( $\text{Ab}_1$ ) and accelerated the electron transfer.<sup>30,31</sup> Secondly, AuBP@Pt nanoparticles were dropped on the surface of electrode, and then the working electrode was obtained. In the electrochemical detection system, AuPd-PDA, as a nanozyme, could catalyze hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) decomposition, during which the change of current was monitored.<sup>26</sup> The detection limit of our designed electrochemical immunosensor is  $15.4 \text{ pg mL}^{-1}$  and the available linear range is from  $0.05 \text{ ng mL}^{-1}$  to  $2000 \text{ ng mL}^{-1}$ . This result made a tremendous progress compared to our previous work, which provided potential detection method for early diagnosis of AD.

## Experimental section

### Apparatus and reagents

The morphology of Au BPs and AuBP@Pt nanostructures was characterized by scanning electron microscopic (SEM, Quanta 250, FEI, USA), transmission electron microscopic (JEOL 200CX TEM, JEOL Ltd., Tokyo, Japan), energy dispersive X-ray (EDX) elemental mapping analysis (Quanta 250, FEI, USA) and UV-vis spectrum (HITACHI, U-4100). Electrochemical measurements were all performed using a CHI760e electrochemical analyzer (ChenHua Instruments, Shanghai, China). The FTIR spectrum was performed by a Nicolet 6700 spectrophotometer (Thermo, USA).

Monoclonal human APOE4 antibody ( $\text{Ab}_1$ ), polyclonal human apolipoprotein E4 antibody ( $\text{Ab}_2$ ), human APOE4 protein and bovine serum albumin (BSA) were purchased from Novus Biologicals Ltd. Hydrogen tetrachloroaurate(III) trihydrate ( $\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$ ), palladium chloride ( $\text{PdCl}_2$ ), chloroplatinic acid ( $\text{H}_2\text{PtCl}_6 \cdot 6\text{H}_2\text{O}$ ) and dopamine were obtained from Sigma-Aldrich. The phosphate-buffered saline (PBS, 0.01 M, pH = 7.4) was used as incubating and washing buffer solution. All chemicals were of analytical grade and used without further purification. All solvents were ultrapure water (Milli-Q, 18.2 M $\Omega$  cm).

### Preparation of AuBP@Pt

Firstly, the Au BPs were prepared by seed-mediated growth according to the ref. 32. In this work, the longitudinal plasmon wavelength of our used Au BPs was about 808 nm (Fig. S3†). Secondly, the AuBP@Pt nanostructure was prepared by adding Au BPs (OD = 2, 2 mL) with a longitudinal plasmon wavelength of 808 nm into a growth solution including CTAB (6 mL, 0.03 M), ascorbic acid (0.24 mL, 0.1 M), and  $\text{H}_2\text{PtCl}_4$  (0.12 mL, 0.01 M). The obtained solution was mixed and then placed in the oven at 65 °C for 6 h. Finally, AuBP@Pt nanostructures could be obtained. In this experiment, the preparation method referred to the previous research about the preparation of Au nanorod core-Pd shell nanostructures.<sup>33</sup>

### Fabrication of GCE/Au/AuBP@Pt electrode

Firstly, glassy carbon electrode (GCE, 3 mm) was polished and sonicated in ethanol and ultrapure water successively for




Fig. 1 The constructed process of  $\text{Ab}_2$  label (a) and the schematic illustration of the APOE4 electrochemical immunosensor (b).



10 min. And then the GCE electrode was dried by  $N_2$ . Secondly, the GCE electrode was electrodeposited with Au nanoparticles. The electrodeposition was proceeded by 20 s in  $H_2SO_4$  (0.5 M) containing  $10\text{ mg mL}^{-1}$   $H AuCl_4$  at  $-0.2\text{ V}$ . Finally,  $10\text{ }\mu\text{L}$  AuBP@Pt solution ( $1\text{ mg mL}^{-1}$ ) was dropped on the surface of electrode surface.

### Fabrication of the electrochemical immunosensor

The GCE/Au/AuBP@Pt electrode was rinsed with ultrapure water for one minute and then was dried by  $N_2$  flow. The construction of sensing interface was carried out on the GCE/Au/AuBP@Pt surface by successive self-assembling procedures. First of all,  $10\text{ }\mu\text{L}$   $Ab_1$  ( $100\text{ }\mu\text{g mL}^{-1}$ ) was dropped onto the surface of GCE/Au/AuBP@Pt electrode and incubated 1.0 h at  $37\text{ }^\circ\text{C}$ . Secondly, bovine serum albumin (BSA,  $1.0\text{ mg mL}^{-1}$ ) was applied to block non-specific binding sites of electrode surface. Thirdly, APOE4 of certain concentration ( $6\text{ }\mu\text{L}$ ) dripped on the surface of electrode and incubated for 1.0 h at  $37\text{ }^\circ\text{C}$ . Finally,  $50\text{ }\mu\text{g mL}^{-1}$   $Ab_2$  label were added and incubated 1.0 h at  $37\text{ }^\circ\text{C}$ . After each step, the surface was washed three times by PBS (0.01 M).

### The measurements of analytical performance

All electrochemical analysis was carried out through three-electrode system. The GCE/Au/AuBP@Pt electrode modified by  $Ab_1$  served as working electrode and Ag/AgCl electrode was used for reference electrode. The counter electrode used platinum electrode. The electrochemical assay was performed by amperometric measurements in 15 mL PBS buffer at  $-0.25\text{ V}$  under constant stirring. When transient currents tended to a steady-state value,  $150\text{ }\mu\text{L}$  of  $H_2O_2$  (400 mM) was rapidly added to the PBS buffer solution. The change of momentary current was monitored.

The selectivity of fabricated electrochemical biosensor was investigated by the same procedure in PBS buffer containing other proteins, such as BSA, APOE2 and APOE3. Moreover, commercial goat serum containing various proteins was used to prove the specificity and potential application value. The detailed procedures were as follows.  $10\text{ }\mu\text{L}$   $Ab_1$  ( $100\text{ }\mu\text{g mL}^{-1}$ ) was dropped onto the surface of GCE/Au/AuBP@Pt electrode and incubated at  $37\text{ }^\circ\text{C}$  for 1.0 h. Then,  $6\text{ }\mu\text{L}$  BSA ( $1\text{ mg mL}^{-1}$ ) was applied to block the non-specific adsorption sites. Thirdly, a  $6\text{ }\mu\text{L}$  diluted goat serum containing different concentration of APOE4 ( $1\text{ ng mL}^{-1}$ ,  $10\text{ ng mL}^{-1}$ ,  $100\text{ ng mL}^{-1}$ ) was dropped onto the surface of electrode at  $37\text{ }^\circ\text{C}$  for 1 h. Finally,  $10\text{ }\mu\text{L}$   $Ab_2$  label ( $50\text{ }\mu\text{g mL}^{-1}$ ) were added and incubated at  $37\text{ }^\circ\text{C}$  for 1 h. Beyond the incubation, other experiments were all performed at room temperature.

## Results and discussion

### Characterization of the AuBP@Pt nanostructures

Before the preparation of AuBP@Pt nanostructures, the Au BPs were prepared by seed-mediated growth according to the ref. 32. The morphology and extinction spectrum were shown in Fig. 2e and S3.† The result demonstrated that the size of Au BPs was




Fig. 2 The EDX mapping analysis (a–d) and TEM image (f) of AuBP@Pt nanostructures. (e) The SEM image of AuBP. (g) The schematic illustrating the variation from AuBP to AuBP@Pt.

about 80 nm length and 30 nm width (Fig. 2e) and the Au BPs had a longitudinal plasmon wavelength of  $\sim 808\text{ nm}$  (Fig. S3†).

And then, the AuBP@Pt nanostructures were prepared by adding Au BPs into a mixed solution including CTAB, ascorbic acid, and  $H_2PtCl_4$  at  $65\text{ }^\circ\text{C}$  for 6 h. The detailed concentration of each component was seen in the Experimental section. The characterization of the AuBP@Pt nanostructures was shown in Fig. 2. Overall, the AuBP@Pt exhibited a nano bipyramid morphology with about 100 nm length and 50 nm width (Fig. 2f). The surface of AuBP@Pt nanostructures was composed of many Pt nanoparticles with a diameter of 2 nm according to the typical TEM images Fig. 2f, which was porous. The porous nanostructures further increased the binding sites of primary antibody. Not only that, the porous nanostructures also enhanced the electron transfer rate, which contributed to enhance the sensitivity of sensor. Moreover, the EDX mapping analysis was carried out and the distribution of Au and Pt elements on the surface was shown in Fig. 2a–d. The result of EDX spectrum showed that the atomic ratio of Au/Pt on the surface of AuBP@Pt was about 48 : 52 (Fig. 2d). No other metallic element was observed, which proved the purity of the AuBP@Pt nanostructures.

### Fabrication of GCE/Au/AuBP@Pt electrode and sensing interface

After the preparation of AuBP@Pt nanostructure, the GCE/Au/AuBP@Pt electrode was constructed by following procedures. Firstly, the GCE electrode was polished and then was electrodeposited with Au nanoparticles according to the ref. 31. And the detailed process was seen in Experimental section. Finally,  $5\text{ }\mu\text{L}$  AuBP@Pt solution was dropped onto the electrode surface. Now a good electrode based on GCE/Au/AuBP@Pt was obtained by a series of procedures above.

As Fig. 3a showed, when Au nanoparticles were electrodeposited on the surface of GCE, the electroactive area significantly increased. After the AuBP@Pt was dropped onto the Au nanoparticles surface, the electroactive area further got larger. Therefore, the introduction of Au/AuBP@Pt nanostructures enhanced the sensitivity of the sensor to some extent. After the construction of the GCE/Au/AuBP@Pt electrode, the electrochemical immunosensor was constructed through successively






Fig. 3 (a) Cyclic voltammograms of GCE, GCE/Au and GCE/Au/AuBP@Pt electrode in aqueous 0.5 M H<sub>2</sub>SO<sub>4</sub> solution. (b) The characterization of surface-modification on GCE/Au/AuBP@Pt electrode: cyclic voltammograms of the GCE/Au/AuBP@Pt electrode (curve a) modified with Ab<sub>1</sub> (curve b), Ab<sub>1</sub> + BSA (curve c), Ab<sub>1</sub> + BSA + APOE4 (curve d) Ab<sub>1</sub> + BSA + APOE4 + Ab<sub>2</sub> label (curve e). The cyclic voltammograms are carried out in 5 mM [Fe(CN)<sub>6</sub>]<sup>3-</sup>/[Fe(CN)<sub>6</sub>]<sup>4-</sup> at scan rates of 50 mV·s<sup>-1</sup>.

self-assembly procedures and the process was studied by CV measurements and electrochemical impedance spectroscopy (EIS). As shown in Fig. 3b, the peak current gradually reduced from curve a to curve f. The GCE/Au electrode showed a peak current of 75 μA (Fig. 3b, curve a). After the GCE/Au/AuBP@Pt electrode was modified with Ab<sub>1</sub>, the peak current decreased significantly (Fig. 3b, curve b), which demonstrated that Ab<sub>1</sub> hindered the electron transfer of electrode surface in some way. And then BSA was used to block the non-specific adsorption sites on the surface. At the moment, the peak current was down to 50% of initial value (Fig. 3b, curve c), which indicated that non-specific binding sites on the surface had been blocked. As shown blue and cyan curve (curve d and e) in Fig. 3b, the peak current decreased again with the modification of APOE4 protein and Ab<sub>2</sub> to the GCE/Au/AuBP@Pt surface.

To further proved the process of assembly, electrochemical impedance spectroscopy (EIS) was carried out as shown in Fig. S7.† The bare GCE/Au/AuBP@Pt exhibits a small resistance (Fig. S7,† curve a). When Ab<sub>1</sub> (Fig. S7,† curve b), BSA (Fig. S7,† curve c), APOE4 (Fig. S7,† curve d) and Ab<sub>2</sub> label (Fig. S7,† curve e) were immobilized layer by layer on the surface of electrode, the resistance increased gradually due to the modified protein. This result was consistent with the conclusion of the CVs. According to above analysis, it was inferred that the sensing interface was constructed successfully. At last, the quantification of APOE4 was monitored by chronoamperometry in the presence of H<sub>2</sub>O<sub>2</sub>.

### The study of sensing performance

To obtain better sensing performance for detection of APOE4, the experimental conditions including the volume of AuBP@Pt solution and the concentration of H<sub>2</sub>O<sub>2</sub> were optimized. As shown in Fig. S4,† the electrochemical current response for the reduction of H<sub>2</sub>O<sub>2</sub> in PBS was largest when the volume of AuBP@Pt was 10 μL. It is inferred that appropriate volume of AuBP@Pt could efficiently improve the analytical performance when the concentration of AuBP@Pt was constant. We inferred that excessive AuBP@Pt could block the electron transfer. Therefore, an optimal volume was 10 μL. Moreover, the concentration of H<sub>2</sub>O<sub>2</sub> was optimized and the result was shown

in Fig. S5.† The optimal concentration of H<sub>2</sub>O<sub>2</sub> was 2 mM. Because higher H<sub>2</sub>O<sub>2</sub> concentration had strong oxidability, which could destroy the interaction of antigen and antibody. In addition, the results about stability was shown in Fig. S6.† The initial response decreased only 5.1% after a storage of 7 days in refrigerator at 4 °C, which indicated the sensor had good stability.

Under the optimal conditions, the developed electrochemical immunosensor based on AuBP@Pt and AuPd-PDA was applied to detect quantitatively APOE4. According to our previous report,<sup>26</sup> the AuPd-PDA nanotubes could catalyze hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) decomposition and the optimal potential was -0.25 V, during which the changes of electrochemical signal (reductive current) could be monitored. Based on this principle, the APOE4 could be detected quantitatively by the change value of current.

The change value of current response ( $\Delta I$ ) were monitored by chronoamperometry when different concentration of human APOE4 were added. According to our previous study, the optimized concentrations of Ab<sub>1</sub> were 100 μg mL<sup>-1</sup> and the concentration of Ab<sub>2</sub> was about 50 μg mL<sup>-1</sup>. As shown in Fig. 4a, the transient current reached a steady state rapidly with add of H<sub>2</sub>O<sub>2</sub> and the change value enhanced with the increase of APOE4 concentration. Fig. 4b showed the relationship between change value of current and logarithm of human APOE4 concentration. The  $\Delta I$  and logarithm of APOE4 concentration from 0.05 ng mL<sup>-1</sup> to 2000 ng mL<sup>-1</sup> existed linear relationship. And the detection limit of our developed electrochemical immunosensor was about 15.4 pg mL<sup>-1</sup> (S/N = 3). According to previous report, the concentration of human APOE4 in serum was about μg mL<sup>-1</sup> level for the individuals who had APOE4 allele.<sup>34</sup> And thus, the detection limit of our designed electrochemical immunosensor based on AuBP@Pt and AuPd-PDA could satisfy the requirements of clinical application in this respect.

Furthermore, compared to the previous methods for the detection of APOE or APOE4, the designed electrochemical immunosensor had a wider linear range from 0.05 ng mL<sup>-1</sup> to 2000 ng mL<sup>-1</sup> and lower detection limit of 15.4 pg mL<sup>-1</sup>. And the detailed comparison was shown in Table S1.† In this work, porous Au/AuBP@Pt substrate materials could increase the




Fig. 4 (a) Amperometric *i-t* results of the APOE4 immunosensor for reduction of H<sub>2</sub>O<sub>2</sub> (2 mM) under constant stirring when detecting different concentrations of human APOE4 protein range from 0.05 ng mL<sup>-1</sup> to 2000 ng mL<sup>-1</sup>. (b) Calibration curve of the designed immunosensor for the detection of APOE4. The equation:  $\Delta I = 18.191 \lg C + 200.78$ ,  $R^2 = 0.9841$ . Error bar = relative standard deviation ( $n = 3$ ).






Fig. 5 (a) Current change value of the APOE4 electrochemical immunosensor for different protein including BSA, APOE2, APOE3, APOE4. (b) The current response of APOE4 electrochemical immunosensor for goat serum containing different concentration human APOE4. (c) The histogram of current change value of (b). The error bars represent relative standard deviation ( $n = 5$ ).

binding sites of antibody and electron transfer rate, which enhanced the sensitivity of sensor. What's more, AuPd-PDA, as a nanoenzyme, could catalyze hydrogen peroxide ( $H_2O_2$ ) decomposition replacing the traditional bio-enzyme, which was more stable than traditional bio-enzyme. Therefore, our designed APOE4 electrochemical immunosensor based on AuBP@Pt nanomaterials and AuPd-PDA nanoenzyme exhibited excellent sensing performance.

### The selectivity, reproducibility of constructed electrochemical immunosensor

The selectivity of developed APOE4 electrochemical immunosensor based on AuBP@Pt and AuPd-PDA was tested. Fig. 5a presented the histogram of the change value of instantaneous current in the presence of  $1 \text{ ng mL}^{-1}$  APOE4,  $1 \text{ } \mu\text{g mL}^{-1}$  BSA,  $1 \text{ } \mu\text{g mL}^{-1}$  APOE2 or  $1 \text{ } \mu\text{g mL}^{-1}$  APOE3 and the PBS buffer as a control. There was an obvious signal response only if human APOE4 existed, which was an average of  $32.33 \text{ } \mu\text{A}$ . But the  $\Delta I$  for BSA, APOE2 and APOE3 were  $0.68$ ,  $1.80$ ,  $2.03 \text{ } \mu\text{A}$ , which accounted for  $2.1\%$ ,  $5.6\%$ , and  $6.2\%$  of the  $\Delta I$  for APOE4, respectively. This result indicated that the selectivity of as-fabricated electrochemical immunosensor was acceptable.

To evaluate reproducibility and clinical potential of the electrochemical immunosensor, the commercial goat serum diluted with PBS buffer was used as electrolyte to detect the APOE4. Three groups of GCE/Au/AuBP@Pt electrodes (each group include 5 electrodes) were used to detect different concentration of human APOE4 protein ( $1.0$ ,  $10$  and  $100 \text{ ng mL}^{-1}$ ) in goat serum. As shown in Fig. 5b and c, a good response for human APOE4 protein in goat serum was observed, which further proved that the APOE4 electrochemical immunosensor had a good selectivity. Moreover, the recovery and RSD for five electrodes were calculated and the result was shown in Table S2.† The RSD of the three groups was all less than  $6\%$ , which manifested that the sensor had a good reproducibility and potential application value in the real biological sample.

## Conclusions

In conclusion, an ultrasensitive electrochemical immunosensor based on AuBP@Pt nanostructures and AuPd-PDA nanozyme was developed for the detection of APOE4. Porous AuBP@Pt

nanomaterials could enhance the binding sites of antibody and electron transfer rate due to large electroactive area and good conductivity. More importantly, AuPd-PDA nanozyme was used to label detection antibody due to excellent catalytic capability and stability, which further amplified the detected signals and increased the sensitivity. Based on these advantages of AuBP@Pt and AuPd-PDA, the constructed electrochemical biosensor exhibited a low detection limit of  $15.4 \text{ pg mL}^{-1}$  ( $S/N = 3$ ) and a wide linear range from  $0.05 \text{ ng mL}^{-1}$  to  $2000 \text{ ng mL}^{-1}$ . Besides, the biosensor displayed good specificity and reproducibility in PBS buffer or commercial goat serum. This work not only provides a strong support for the prevention and early diagnosis of AD susceptible populations but also offers a promising tool for bioanalysis.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The work was supported by Natural Science Foundation of Education Department of Henan Province (18B150011, 19A430018), Natural Science Foundation of China (Grant No. 51902123).

## Notes and references

- C.-C. Liu, N. Zhao, Y. Fu, N. Wang, C. Linares, C.-W. Tsai and G. Bu, *Neuron*, 2017, **96**, 1024–1032.
- R. D. Bell, E. A. Winkler, I. Singh, A. P. Sagare, R. Deane, Z. Wu, D. M. Holtzman, C. Betsholtz, A. Armulik, J. Sallstrom, B. C. Berk and B. V. Zlokovic, *Nature*, 2012, **485**, 512–516.
- K. Nishitsuji, T. Hosono, T. Nakamura, G. J. Bu and M. Michikawa, *J. Biol. Chem.*, 2011, **286**, 17536–17542.
- T. Kanekiyo, H. Xu and G. Bu, *Neuron*, 2014, **81**, 740–754.
- C.-C. Liu, T. Kanekiyo, H. Xu and G. Bu, *Nat. Rev. Neurol.*, 2013, **9**, 106–118.
- M. Wang, J. Chen and I. V. Turko, *Anal. Chem.*, 2012, **84**, 8340–8344.
- P. M. Sullivan, B. Han, F. Liu, B. E. Mace, J. F. Ervin, S. Wu, D. Koger, S. Paul and K. R. Bales, *Neurobiol. Aging*, 2011, **32**, 791–801.
- M. Vincent-Viry, F. Schiele, R. Gueguen, K. Bohnet, S. Visvikis and G. Siest, *Clin. Chem.*, 1998, **44**, 957–965.
- K. Taddei, R. Clarnette, S. E. Gandy and R. N. Martins, *Neurosci. Lett.*, 1997, **223**, 29–32.
- E. Morales-Narváez, H. Montón, A. Fomicheva and A. Merkoçi, *Anal. Chem.*, 2012, **84**, 6821–6827.
- X. Yi, Y. Xia, B. Ding, L. Wu, S. Hu, Z. Wang, M. Yang and J. Wang, *ACS Sens.*, 2018, **3**, 2402–2407.
- Y. Liu, L.-P. Xu, S. Wang, W. Yang, Y. Wen and X. Zhang, *Biosens. Bioelectron.*, 2015, **71**, 396–400.
- B. Shui, D. Tao, J. Cheng, Y. Mei, N. Jaffrezic-Renault and Z. Guo, *Analyst*, 2018, **143**, 3549–3554.
- M. Negandary and H. Heli, *Talanta*, 2019, **198**, 510–517.



- 15 Z. Guanhui, W. Yaoguang, L. Xiaojian, Y. Qi, D. Xue, D. Bin, C. Wei and W. Qin, *Anal. Chem.*, 2019, **91**, 1989–1996.
- 16 T. Shu, L. Su, J. Wang, C. Li and X. Zhang, *Biosens. Bioelectron.*, 2015, **66**, 155–161.
- 17 B. R. Li, Y. J. Hsieh, Y. X. Chen, Y. T. Chung, C. Y. Pan and Y. T. Chen, *J. Am. Chem. Soc.*, 2013, **135**, 16034–16037.
- 18 R. Xu, D. Wei, B. Du, W. Cao, D. Fan, Y. Zhang, Q. Wei and H. Ju, *Biosens. Bioelectron.*, 2018, **122**, 37–42.
- 19 G. Zengqiang, L. Yueyun, Z. Chunyan, Z. Shuan, J. Yilei, L. Faying, D. Hui, L. Xinjin, C. Zhiwei and W. Qin, *ACS Appl. Mater. Interfaces*, 2019, **11**, 12335–12341.
- 20 J. Qin, M. Cho and Y. Lee, *ACS Appl. Mater. Interfaces*, 2019, **11**, 11743–11748.
- 21 Y. Wang, D. Fan, G. Zhao, J. Feng, D. Wei, N. Zhang, W. Cao, B. Du and Q. Wei, *Biosens. Bioelectron.*, 2018, **120**, 1–7.
- 22 K. D. Gilroy, A. Ruditskiy, H.-C. Peng, D. Qin and Y. Xia, *Chem. Rev.*, 2016, **116**, 10414–10472.
- 23 L. Zhang, Z. Xie and J. Gong, *Chem. Soc. Rev.*, 2016, **45**, 3916–3934.
- 24 S. Sarina, H. Zhu, E. Jaatinen, Q. Xiao, H. Liu, J. Jia, C. Chen and J. Zhao, *J. Am. Chem. Soc.*, 2013, **135**, 5793–5801.
- 25 Y. Liu, X. Weng, K.-K. Wang, Y. Xue, A.-J. Wang, L. Wu and J.-J. Feng, *Sens. Actuators, B*, 2017, **247**, 349–356.
- 26 G. He, F. Gao, W. Li, P. Li, X. Zhang, H. Yin, B. Yang, Y. Liu and S. Zhang, *Anal. Methods*, 2019, **11**, 1651–1656.
- 27 Y. Liu, K. Ai and L. Lu, *Chem. Rev.*, 2014, **114**, 5057–5115.
- 28 S. Wang, B. Y. Guan, L. Yu and X. W. Lou, *Adv. Mater.*, 2017, **29**, 1702724.
- 29 W. Hu, G. He, H. Zhang, X. Wu, J. Li, Z. Zhao, Y. Qiao, Z. Lu, Y. Liu and C. M. Li, *Anal. Chem.*, 2014, **86**, 4488–4493.
- 30 Y. Wei, Y. Li, N. Li, Y. Zhang, T. Yan, H. Ma and Q. Wei, *Biosens. Bioelectron.*, 2016, **79**, 482–487.
- 31 X. Zhang, Y. Li, H. Lv, J. Feng, Z. Gao, P. Wang, Y. Dong, Q. Liu and Z. Zhao, *Biosens. Bioelectron.*, 2018, **106**, 142–148.
- 32 Q. Li, X. Zhuo, S. Li, Q. Ruan, Q.-H. Xu and J. Wang, *Adv. Opt. Mater.*, 2015, **3**, 801–812.
- 33 H. Chen, F. Wang, K. Li, K. C. Woo, J. Wang, Q. Li, L.-D. Sun, X. Zhang, H.-Q. Lin and C.-H. Yan, *ACS Nano*, 2012, **6**, 7162–7171.
- 34 D. Lefranc, P. Vermersch, J. Dallongeville, C. Daems-Monpeurt, H. Petit and A. Delacourte, *Neurosci. Lett.*, 1996, **212**, 91–94.

